179 related articles for article (PubMed ID: 18192538)
1. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
2. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
7. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
8. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
Yousef AM; Arafat T; Bulatova NR; Al-Zumyli R
J Clin Pharm Ther; 2008 Aug; 33(4):439-49. PubMed ID: 18613862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
11. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function.
Yang BB; Kido A; Salfi M; Swan S; Sullivan JT
J Clin Pharmacol; 2008 Sep; 48(9):1025-31. PubMed ID: 18524995
[TBL] [Abstract][Full Text] [Related]
16. On the pharmacokinetics of latamoxef in normal and impaired renal function.
Höffler D; Koeppe P; Moecke D
Arzneimittelforschung; 1984; 34(3):317-20. PubMed ID: 6539614
[TBL] [Abstract][Full Text] [Related]
17. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.
Guay DR; Matzke GR; Bockbrader HN; Dancik J
Clin Pharm; 1983; 2(2):157-62. PubMed ID: 6883944
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal function on the pharmacokinetics of palifermin.
Gillespie B; Zia-Amirhosseini P; Salfi M; Kakkar T; Wang J; Gupta S; Smith B; Robson R; Sullivan JT
J Clin Pharmacol; 2006 Dec; 46(12):1460-8. PubMed ID: 17101745
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
Darwish M; Chang S; Hellriegel ET
Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
